Codexis, Inc. CDXS
NASDAQ · United States · Process Industries
$1.36-0.03 (-2.16%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform. The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise cont
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.